Prostate Cancer

News alerts, weekly reports and conference planners

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval Bayer Press Release - 4 days (New B) darolutamide Sensitive : A1 Bayer Press Release - 4d	darolutamide Sensitive: A1 - Approval Bayer Press Release - 4 days darolutamide Sensitive : A1 Bayer Press Release - 4 days - (New B)
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	pembrolizumab Sensitive: C4 – Case Studies BMJ Case Rep - 1 week (New C4) pembrolizumab Sensitive : C4 BMJ Case Rep - 1wk	pembrolizumab Sensitive: C4 – Case Studies BMJ Case Rep - 1 week pembrolizumab Sensitive : C4 BMJ Case Rep - 1 week - (New C4)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1
FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide mesylate injectable suspension Sensitive: A1 - Approval leuprolide mesylate injectable suspension Sensitive : A1	leuprolide mesylate injectable suspension Sensitive: A1 - Approval leuprolide mesylate injectable suspension Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
PALB2 mutation	Prostate Cancer	PALB2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CHEK1 mutation	Prostate Cancer	CHEK1 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	abiraterone acetate Resistant: A2 - Guideline abiraterone acetate Resistant : A2	abiraterone acetate Resistant: A2 - Guideline abiraterone acetate Resistant : A2
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	enzalutamide capsule Resistant: A2 - Guideline enzalutamide capsule Resistant : A2	enzalutamide capsule Resistant: A2 - Guideline enzalutamide capsule Resistant : A2
RAD51B mutation	Prostate Cancer	RAD51B mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
RAD51C mutation	Prostate Cancer	RAD51C mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
RAD51D mutation	Prostate Cancer	RAD51D mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2

Prostate Cancer

Associations(421)

Associations
(421)